ortic stenosis (AS) represents the most frequent heart valve disease in industrialized countries, with a prevalence, strongly increasing with age, from 2.5% by age 75, up to 8% at age 85 years. 1, 2 With the lengthening of life expectancy, the population of old patients with AS is expected to grow in the future. The progressive onset of symptoms such as angina, syncope, and congestive heart failure usually leads to death within 2 to 3 years, unless the patient undergoes surgical aortic valve replacement (SAVR), the current gold standard for the treatment of severe symptomatic AS. The American, European and Japanese guidelines suggest that all cases of symptomatic severe AS with no clinical contraindications for surgery, such as the "oldest-old", are indicated for surgery. [3] [4] [5] In all of these guidelines, age alone is not a contraindication for surgery.
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Operative mortality of SAVR is quite low, even in elderly patients when properly selected, and long-term results have been shown to be satisfactory. 6 In particular, recent studies have reported operative mortality around 10% (range, 4.3-13.7%) for isolated SAVR in the octogenarian, concluding that patients who undergo SAVR have better outcomes than who are treated conservatively. 7-9 On the other hand, no such information is available for the Japanese population. In this issue of the Journal, Ohno et al demonstrate the benefits of SAVR compared with conservative medical therapy even in elderly Japanese with symptomatic AS. 10 Their study shows that treatment choice was mainly driven by age. Medical therapy was often selected for older patients and the percentage of those treated surgically decreased with the patient's age, with no patient aged over 85 years treated (80% of the patients in the medical group were octogenarians vs. 14% in the surgical group).
However, as the surgical risk is definitely higher in elderly patients when severe comorbidities are present, 11 many patients are not referred for SAVR, and are left with a dismal prognosis. In the Euro Heart Survey published in 2005, 33% of patients with symptomatic severe valve disease were not referred for surgery, owing to advanced age, left ventricular dysfunction, or the presence of multiple coexisting conditions. 12 In such patients, a less invasive treatment may be a desirable alternative. 1 Balloon aortic valvuloplasty (BAV) nowadays is rarely used, mainly because of its limited longterm efficacy, and should be left as a bridge to transcatheter aortic valve implantation (TAVI) or SARV in patients with poor left ventricular function.
TAVI currently represents a viable alternative to conventional SAVR for patients with severe, symptomatic AS at high risk of operative mortality. 13 In fact, TAVI has consistently demonstrated good results from the pioneering reports to the first randomized trial vs. medical therapy, showing that this relatively new treatment is safe and effective in inoperable patients and in patients at high risk for surgery. 14 Since the first-in-man procedure in 2002, several improvements have been achieved in TAVI device technologies and procedural management, leading to incremental success rates. Nowadays, 2 TAVI devices are under postmarketing surveillance in Europe and evaluation for the Food and Drug Administration in the USA: the balloon-expandable Edwards SAPIEN prosthesis (Edwards Lifesciences, CA, USA) and the self-expandable CoreValve Revalving prosthesis (Medtronic, MN, USA) ( Figure) .
We have recently demonstrated, in an observational registry study, that in a population of high-risk subjects with several comorbidities, TAVI was associated with lower cardiac mortality compared with medical management and BAV (Table) . Furthermore, the clinical outcome at 6 months was similar to that of less sick patients undergoing SAVR. 9 PARTNER, the first multicenter and randomized clinical trial in a wider population, confirmed these results, comparing TAVI with standard therapy in high-risk patients. In particular, in that study, 358 patients with severe AS, whom surgeons considered to be 
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unsuitable candidates for surgery, were randomly assigned to standard therapy (including BAV) or transfemoral transcatheter implantation with the Edwards SAPIEN heart-valve system. The primary endpoint was the rate of death from any cause. At 1 year, the rate of death from any cause, the rate of the composite endpoint of death from any cause or repeat hospitalization and the rate of cardiac symptoms (New York Heart Association class III or IV) were all significantly lower among patients who had undergone TAVI than among those who had received standard therapy. It seems important to underline that the device used in this trial was the old one that has been improved in its technology. Additional recent evidence has shown that, in high-risk patients with severe AS, transcatheter and surgical procedures for aortic valve replacement were associated with similar rates of survival at 1 year, although there were important differences in periprocedural risks. 15 At the moment, TAVI is not performed in Japan, but if it is approved it will be helpful for the prognosis of high-risk Patients referred for TAVI constitute a heterogeneous population, ranging from those too frail and sick to be offered any intervention, to those who are operable but at increased risk compared with the standard patient referred for SAVR. Cardiologists and surgeons must work as a team to select the best candidates, perform the procedure, and, finally, evaluate the results.
The decision for an appropriate treatment is often related to scoring methods, which have limitations in predicting mortality rate in these patients. An emerging need is for a dedicated risk score for patients suitable for TAVI, because as with those we are accustomed to use it for it is difficult to identify some important characteristics that can affect prognosis.
In conclusion, medical management alone demonstrates a high mortality rate, and the addition of BAV, although providing transient symptomatic relief, does not favorably affect survival. TAVI and SAVR can be performed in appropriately selected high-risk patients with good early and long-term outcomes. 
